Cenedella.de

Patient Advocate since 1977.


Leave a comment

Dr. Franjo Grotenhermen – HERO!

Solidarity for abandoned cannabis patients.

Dr. med. Franjo Grotenhermen Employee of the nova Institute, Chairman of the Cannabis Association as Medicine (ACM)
Dr. med. Franjo Grotenhermen, photo: Archive

 

The well-known physician and chairman of the Cannabis Association as a medicine (ACM) Dr. Franjo Grotenhermen has made a moving decision. Although certain positive aspects could be felt in parts through the enacted cannabis-as-medicine law, there would be enough problems in the entire treatment area, which now led to a drastic measure. During the ACM Annual General Meeting in Frankfurt on May 12, 2017, the medical doctor, who has been advocating medical medicine for many years, declares his decision not to eat any food for the next one to two weeks as a result of solidarity with the many cannabis patients left alone.
Doctor Franjo Grotenhermen joins the hunger strike.

 


Dr. Franjo Grotenhermen at the ACM Annual General Meeting 2017 explains hunger strike.

 

The drug policy speakers of the parties were informed before Dr. Franjo Grotenhermen of the warnings – an honorary man.


Leave a comment

Legalize It, a Zurich-based group, has launched a campaign to legally regulate cannabis across Switzerland

Could Switzerland Become the First European Country to Legally Regulate Cannabis?

Nine years after a Swiss referendum failed to gain public approval for cannabis legalisation, a campaign group has reignited the movement for reform.

Legalize It, a Zurich-based group, has launched a campaign to legally regulate cannabis across Switzerland. The objectives of the initiative, Legalize It describes, are three-fold: to allow adults the “freedom and right to consume cannabis”, to prevent those who seek cannabis from having to purchase from the “black market”, and to ensure increased investment into drug use prevention, related research, and social security. The funds for such investment, the group says, will be acquired from the taxation of cannabis sales, and savings on law enforcement expenditure.

The campaign comes in the form of a federal popular initiative, a legislative instrument by which Swiss citizens can suggest changes in the law. If the proposal garners 100,000 valid signatures from Swiss citizens, it will be put forward for debate by the Federal Council, the country’s highest executive authority, and the Federal Assembly, the highest legislative authority.

The Federal Palace of Switzerland. Source: Wikimedia Commons

The cultivation, sale, and use of cannabis are outlawed in Switzerland in almost all cases, however punishment for minor possession is relatively light. Under the current law, an adult found to be in possession of up to 10 grams of cannabis will be fined 100 Swiss francs (£78), and will not be criminally prosecuted. In 2015, there were a total of 18,366 such fines across Switzerland.

Around three percent of adult Swiss residents use cannabis monthly, and almost 40 per cent of adults claim to have used it at least once in their life, according to Addiction Monitoring in Switzerland.

An attempt to legally regulate cannabis was resoundingly opposed by the public in a 2008 referendum, in which 63 per cent of voters opposed the measure. However, the public’s view on the subject has changed over the past decade, according to Nino Forrer, spokesperson for Legalise It.

“Many other countries have legalised or decriminalised cannabis in some form since 2008 and the results are good […] Based on this new data, the Swiss people will see more benefits than harms in legalising cannabis, I’m sure”, Forrer told TalkingDrugs.

“There has not been a massive rise in cannabis consumption among the youth [in places that have legalised cannabis], no surge in traffic accidents, no massive increased health costs. Instead, many jurisdictions have put the extra money from cannabis taxes into public healthcare, infrastructure, and schools in order to improve the standard of living for their people.”

A legal cannabis crow in Colorado. Source: Brett Levin

For example, in 2016, the US state of Colorado collected over $150 million in cannabis sale taxes, of which around $50 million was directed to school projects. Similarly, Legalize Itclaims that taxing the drug could raise 100 million Swiss francs (£78 million) each year, based on their estimates of consumption rates.

Forrer believes that the success of foreign initiatives, such as that in Colorado, may be enough for the Swiss authorities and public to support Legalize It’s new campaign – but only if the message can be effectively be delivered.

“We have had very good responses so far! Many people in Switzerland were waiting for this initiative, so they are very happy that we have started it”, Forrer told us.

“Now, we will try to inform the public as much as possible in order to gather a strong activist base all over the country. Mass media affects our perception of cannabis to a large extent, so good press is needed in order to win over the minds of Swiss people”.

If this initiative proves successful, Switzerland could become the first country in Europe to introduce a legally regulated cannabis market.

Avinash Tharoor is the Editor of TalkingDrugs. He tweets at @AvinashTharoor


Leave a comment

German researchers seek 25,000 marijuana users for study

http://www.ibtimes.co.uk/pot-smokers-wanted-german-researchers-seek-25000-marijuana-users-study-1618629

German researchers are hoping to get government backing for a new study that would see the recruitment of 25,000 recreational marijuana smokers.

The Research Initiative on Cannabis Consumption are seeking government approval to analyse the cannabis users in order to understand the effects of the drug after several years of use.

Their application is aimed at conducting a “Scientific Study on Cannabis Sequences for Mentally Healthy Adult Consumers” they say.

Germany legalised marijuana for medicinal purposes earlier in 2017 with new powers given to doctors to prescribe the drug to seriously ill patients at their discretion.

This, researchers say, paves the way for a new study analysing the longer-term effects of the drug.

Cannabis for recreational use is still illegal, but that hasn’t stopped 2,000 people already signing up for the study, say the researchers.

The group announced plans to begin the study in November 2016 saying it wanted to analyse the mental effects on those addicted to the drug.

“In Germany several million people regularly get high on cannabis,” wrote lawyer and chief executive of the project Marko Dörre in a statement released after the plans were submitted.

“It is time that science becomes more engaged with recreational use.”

Marijuana
German researchers are hunting for 25,000 cannabis smokers for a new study.Reuters/John Vizcaino

As part of the study, those selected would be permitted to pick up 30 grams of pharmaceutical cannabis, usually reserved for medical patients, on a monthly basis.

Researchers are prohibiting anyone under 18, first-time marijuana smokers, as well as candidates with high-risk of addiction or psychiatric problems, from taking part in the study.

Before the new act on the Amendment of Narcotics Regulations passed earlier this year, only around 1,000 people with serious medical conditions were permitted to use cannabis.

“With the law implemented in March changing controlled substance regulations, the German parliament took on a new risk assessment of cannabis,” said Dörre.

“The new assessment will also benefit science.”

The BfArM declined to comment to Tagesspiegel as to whether it had in fact received the application or the chances of it being approved.


Leave a comment

https://cenedella.de/ * Philip J. Cenedella IV * International Cannabis Consultant * Germany, Europe, USA and Canada markets * Medical Marijuana Patient Advocate since 1977 * Assist with Business Development, Licensing, Partnerships, and Strategic Direction.

Philip J. Cenedella IV

Bio

https://cenedella.de/
Philip J. Cenedella IV
International Cannabis Consultant
Medical Marijuana Patient Advocate since 1977.

First and foremost, Phil is a patient advocate for 4 decades having grown up in New York during the Rockefeller Drug Law years, then establishing himself in San Diego during the push for legalization there in the’ 90s.  Now he is situated in Germany during its historic transition into the leadership role of the European Cannabis industry.

Phil is uniquely qualified to help you establish your international business strategy having served as a Founding Board Member of the World Trade Center San Diego, a Lead Consultant for Deutsche Telekom, The California Trade and Investment Office, Deutsche Bank, IBM, San Diego Economic Development Board and many other entities.  He puts his years of business development, sales and distribution expertise to work for you in a highly professional, ethical and effective manner.

40 Years Experience:
Phil was born in Buffalo on the shores of the US/Canadian border, spent most of his life in San Diego overlooking the US/Mexico border, and now is living in Europe with its open borders and the opening of its legal Cannabis industry.

As a C-level business development executive in the technology and construction sectors, and a Founding Board of Director for the World Trade Center San Diego and San Diego Software Council, Phil has facilitated and closed sales and strategic partnerships worldwide.

Phil has also been Lead Consultant for the California Trade and Investment Office in Germany and catalyst for the CAL-IT Investment Forum in London.

He has served as a consultant for IBM, George Clinton, Deutsche Telekom, iSeeTV,  San Diego Convention Center, FINDLAW, Chaparral Computers and Networks, San Diego Economic Development Corporation, Deutsche Bank and many others in the Cannabis space (to remain confidential).

Phil is a USA citizen with an EU Work/Residence Permit.  He has exactly 40 years of firsthand knowledge of all aspects of our Industry and is a C-level International business development specialist who is highly professional yet very easy to work with.  He provides your firm with Strategic guidance and the ability to help you to increase your sales channels, distribution networks, and strategic partnerships.

Education:
1984, University of Dayton B.A. Psychology, Music minor-emphasis

Skill Level:
Sales 98%
Business Development 98%
International  trade 98%
Cannabis Industry 420%

Testimonials

 Who is Phil:
“Phil is an absolute professional. Flexible, hardworking and driven. His results were great and we highly recommend his services.” – BLF, NYC

“Phil has boundless enthusiasm and always applies 100% effort to all he does. Phil researched the US market for…. The USA became our best market by far, and I know that we would never have broken into that extremely tough market without Phil. His combination of broad based business knowledge, willingness to learn, team spirit and superb networking skills is very rare and extremely valuable. Always positive, he was a joy to work with. I thoroughly recommend him.” – GRB, UK

“Phil Cenedella has been my contact for several years and I have found him to be the consummate professional. He will always promptly return a call or provide me an answer to an inquiry. He is always “on-it” and truly treats a client as if they were part of his extended family. It’s very rare these days to find someone as dedicated to his business and his clients as Phil. Phil has all the characteristics of what I look for when I have occasion to be expanding my staff. He is honest to a fault, dedicated, sincere and is the paramount reason for my firm’s continuing…….” – DF ,USA

“Phil is the most personable, genuine, charismatic and effective business development manager I have had the pleasure to work with. He instills trust and confidence!”- JFL, EU

“Phil is family.” – George Clinton
Volunteer Positions:    Founder, Dayton and La Jolla Human Trafficking Accords, Founder, St. Vincent de Paul Christmas Caroling and Limo Party, Volunteer, Americans for Safe Access, Advisor, City of Hope – Dubai  Key accomplishments:  Assisted with the freeing from prison a child victim of human trafficking serving life without parole, initiated Goldman Sachs’ divestment of a human-trafficking related publication, assisted advocates on the frontlines in Dubai, Ohio, California and elsewhere.


Leave a comment

CANADA: ‘An awful lot of expertise’: Black market marijuana growers shouldn’t be shut out of legal market, says task force chair

‘An awful lot of expertise’: Black market marijuana growers shouldn’t be shut out of legal market, says task force chair

Adrian Wyld/ The Canadian Press”We didn’t want all those people excluded automatically from the possibility of participating in some way,” Anne McLellan, now a senior advisor at Bennett Jones LLP, said. Twitter Google+ LinkedIn Email Typo? MoreBlack market marijuana growers should be included in the legal market as they can provide valuable expertise as it evolves, Anne McLellan, chair of the federal government’s task force on legalization, said Monday.McLellan said the Task Force on Cannabis Legalization and Regulation, whose recommendations were broadly adopted in the government’s proposed Cannabis Act, concluded that previous criminal convictions during marijuana’s century of prohibition “shouldn’t be an automatic bar to them coming into the legal system.”“We didn’t want all those people excluded automatically from the possibility of participating in some way,” McLellan, now a senior advisor at Bennett Jones LLP, said in an interview with the Financial Post on the sidelines of a conference on cannabis regulation organized by the Ryerson University in Toronto.The task force’s November report called on the federal government to set up a system that allows various-sized producers to participate, including independent and craft growers.“There are lots of people who are producing now illegally — we talk about artisinal and craft producers — we want a diversity of producers,” McLellan said.“There’s an awful lot of expertise that’s outside the legal system right now and you wouldn’t want to lose all that.”RelatedMarketing restrictions to help small marijuana brands compete against deep-pocketed players: panel‘Turning green into green’: Payment startup aims to capitalize on banking void for marijuana companiesSome Canadian pot activists, including Marc and Jodie Emery, have expressed their disappointment that the draft legislation sets up a system that favours “big marijuana” because the federal government will strictly regulate and license who can produce the plant for sale. Under the current medical marijuana regime, Ottawa has handed out some 40 licences to produce, a small fraction of the number of applicants. However, McLellan points out that producing, manufacturing or selling pot are not the only economic opportunities in the coming multi-billion dollar legal marijuana market.“There are other ways for people to be involved in this industry. People focus on production or manufacturing, retail, and that’s all important, but that’s only the most visible part,” she said.“A lot is going to happen here and there are so many access points for people to be involved.”There are also a plethora of weed-related businesses —from fertilizers to security services to payment processors — carving niches in the space ahead of legalization expected in July 2018.Jodie and Marc Emery, owners of Cannabis Culture, at their store on Church Street in Toronto. They are quickly expanding their empire of dispensaries across Canada and are determined to do so regardless of whether the coming recreational market legalizes dispensaries like theirs. ” data-medium-file=”http://wpmedia.business.financialpost.com/2017/02/fp0204-gs-emergy-web.jpg?quality=60&strip=all&w=300″ data-large-file=”http://wpmedia.business.financialpost.com/2017/02/fp0204-gs-emergy-web.jpg?quality=60&strip=all&w=620″ class=”size-large wp-image-734308″ alt=”Tyler Anderson/National Post” src=”http://wpmedia.business.financialpost.com/2017/02/fp0204-gs-emergy-web.jpg?w=620&quality=60&strip=all&h=389″ width=”620″ height=”389″ srcset=”http://wpmedia.business.financialpost.com/2017/02/fp0204-gs-emergy-web.jpg?w=620&quality=60&strip=all&h=389 620w, http://wpmedia.business.financialpost.com/2017/02/fp0204-gs-emergy-web.jpg?w=1240&quality=60&strip=all&h=778 1240w, http://wpmedia.business.financialpost.com/2017/02/fp0204-gs-emergy-web.jpg?w=140&quality=60&strip=all&h=88 140w, http://wpmedia.business.financialpost.com/2017/02/fp0204-gs-emergy-web.jpg?w=300&quality=60&strip=all&h=188 300w, http://wpmedia.business.financialpost.com/2017/02/fp0204-gs-emergy-web.jpg” style=”max-width:100%;” />


Leave a comment

Canadian pot companies see medical exports growing under Trudeau law

http://www.columbian.com/news/2017/apr/21/canadian-pot-companies-see-medical-exports-growing-under-trudeau-law/

By Josh Wingrove and Jen Skerritt, Bloomberg News

OTTAWA, Canada — Canada’s push to legalize recreational marijuana is rippling beyond its borders as companies move to boost exports of medicinal pot.

Prime Minister Justin Trudeau’s government unveiled its framework last week, quelling concern it would clamp down on export permits for existing medical-pot producers such as Canopy Growth Corp. and Aurora Cannabis Inc. Those companies, which have a head start on the legal recreational market, will continue to be allowed to export marijuana to countries such as Germany and Australia for medical and scientific use.

“It might not be so limited,” said Emily Larose, a partner with law firm Cassels Brock who specializes in cannabis regulation. Industry fears of onerous export restrictions have receded over the past year as bureaucrats typically approve any permit so long as the main requirements are met. “The way in which they’ve been granted so far seems to be more box-ticking.”

Companies in Canada, the second country and first major economy to unveil plans for legalization of recreational pot, have already secured investments and partnerships in countries where support for legalized medical marijuana is gaining ground. The global cannabis market may be worth $200 billion, with the medical market accounting for 25 percent to 50 percent of that, Daniel Pearlstein, a research analyst in Toronto at Eight Capital, said by email.

Canopy is already exporting to Brazil and Germany. Last year, the Smith Falls, Ontario-based company acquired pharmaceutical distributor MedCann GmbH, which has placed its cannabis strains in German pharmacies.

Bedrocan Canada Inc., a unit of Canopy, exported 10 kilograms of dried cannabis to Brazil to be used in a clinical study targeting epilepsy and pain management, according to a November statement.

Canada is emerging as a leader in public policy around marijuana and other countries will need its know-how as they shift toward making cannabis and cannabinoids part of standard medical treatment, said Chief Executive Officer Bruce Linton. That gives Canopy the chance to export product while the domestic industry makes that transition, and to set up production on the ground once it has, he said.

“All of these jurisdictions are contemplating or structuring a way in which production will occur in them,” Linton said by phone. “We are actually an exporter of public policy.”

That meshes with Trudeau’s view for the future of the Canadian economy: one pivoting from raw resource extraction toward white-collar jobs in the services sector.

“You’re going to develop know-how on how to make this stuff,” said Eileen McMahon, a partner at Torys LLP and chair of the law firm’s intellectual property and food and drug regulatory practices. “That know-how arguably could be used” outside Canada under the Trudeau law, she said, adding it’s possible “employees with that expertise could cross the border.”

Aurora intends to be a “significant” player in the Australian market and is looking at others as well, said Cam Battley, an executive vice president. The Cremona, Alberta-based company plans to use its capital and experience to export its product, and to set up in countries where marijuana may soon be legal, he said.

“Canada more broadly is a leader in the cannabis industry,” Battley said by phone. “That gives us a lot of potential power in other markets.”

Exports will be allowed “as long as they meet the strict regulatory requirements,” lawmaker Bill Blair, a former police chief and Trudeau’s point man on pot legalization, said in an interview. He brushed aside questions about whether the government wants to encourage companies to be exporters. “We want to make sure there is a viable industry capable of supplying that well-regulated retail market” domestically in Canada.

The government has to issue export permits repeatedly, and could clamp down, change guidelines or slow its issuing of permits if it wanted to cool the market.

In a notice posted last year, Canada said it “does not support facilitating a regime premised on servicing global demand given the associated public health, safety and security risks” and that export “would be permitted under very limited circumstances.” Fears stoked in industry by that notice have since eased, Larose said.

Aurora secured a 19.9 percent stake last month in Cann Group, the first Australian company to be licensed for research and cultivation of medical cannabis for human use.

Aphria Inc., based in Leamington, Ontario, is investing $25 million in a dispensing operation in Florida, the company said April 4. Aphria’s U.S. expansion strategy is to target key states that have approved medical marijuana, according to the statement.

Canada’s legalization effort may violate its obligations under international law, Steven Hoffman, director of the University of Ottawa’s Global Strategy Lab, wrote in a Globe and Mail editorial this week. “Unless we change our constitution, Canada cannot legally legalize cannabis without either renegotiating the U.N. treaties, obtaining special exceptions, finding creative workarounds, or withdrawing from them,” he wrote.

The government believes its restrictions on production or sale outside its strictly regulated regime, as well as restrictions on some exports and use by minors, keeps it onside, Blair said.

“We believe this enables us to uphold and maintain our obligations under those treaties,” he said, speaking in an interview after Justice Minister Jody Wilson-Raybould referred questions on the matter to Blair.


Leave a comment

Why is Big Pharma fighting Medical Marijuana so hard? A new report published in Health Affairs found that if all states had legalized medical cannabis in 2014, Medicaid could have saved $1 billion in spending on prescriptions…could be one of the reasons.

If all states had had a medical marijuana law in 2014, we estimated that total savings for fee-for-service Medicaid could have been $1.01 billion. 

I write about retail and cannabis.

A new report published in Health Affairs found that if all states had legalized medical marijuana in 2014, Medicaid could have saved $1 billion in spending on prescriptions.

The study by Ashley C. Bradford and W. David Bradford examined whether states with medical marijuana laws saw changes for prescription drugs among Medicare Part D enrollees. Their analysis covered data between 2007 to 2014 and found that patients did indeed substitute medical marijuana for FDA-approved prescription drugs in these states.

“Total estimated Medicaid savings associated with these laws ranged from $260.8 million in 2007 to $475.8 million in 2014,” the study states. Granted this is only 2% of the total Medicaid drug spending for 2014, which was $23.9 billion, but it is still substantial savings. The Bradfords estimate that if all states had legalized medical marijuana in 2014, “The national savings for fee-for-service Medicaid would have been approximately $1.01 billion.” This works out to an average per state savings of $19.825 million a year.

However, only 26% of Medicaid customers are enrolled in the fee-for-service program. The study notes that if they applied their analysis equally to Medicaid managed care, then the savings could jump to a whopping $3.89 billion. Again, this is only if all states legalized medical marijuana.

Granted the savings are mostly enjoyed by private insurers that run the plans, but the Bradfords suggest that state governments could reduce their payments to the insurers as prescription drug costs fall.

The study only looked at conditions that could be treated with medical marijuana and the prescription drugs that would be affected. This included anxiety, depression, glaucoma, nausea, pain, psychosis, seizures, sleep disorders and spasticity. According to the study, “the differences ranged from a 42% reduction for prescriptions used to treat nausea to a 15% reduction for spasticity.” The Bradfords also found a 13% decline in depression drug prescriptions, a 12% drop in psychosis drug prescriptions and an 11% slide in pain drugs. There was no significant drop in drugs used for anxiety, glaucoma or sleep disorders.

The Bradfords noted that their study was challenged by the fact that states keep changing their medical marijuana laws and expanding approved conditions. Furthermore, they only had data available from fee-for-service Medicaid prescriptions. Managed care patient data was inconsistent. Thus, their findings are really lower than what the true savings could really be, suggesting it could be in the billions.